Shenzhen Efung Capital is one of the earliest venture capital institutions that specialized in biomedicine investment in China. Efung has a high-caliber management team and an experienced investment team, which consist of MDs/PhDs graduated from professional institutions at home and abroad. It focuses on medical and healthcare sectors, especially in VC and PE investment in biopharmaceuticals and high-end medical devices. Throughout these years, Efung has explored profoundly the potentials of healthcare industry, and has invested over 50 prominent companies globally, such as Chipscreen Bioscience, Frontier Biotech, Ascentage Pharma, Lifotronic Technology, Apexigen and Centrexion et al.


Efung Capital has demonstrated a solid track record, and has achieved strong revenue and earnings growth. It was recognized as “Zero2IPO Group2020 Best Healthcare Investment Institution TOP30”, “ChinaVenture 2019 Best Exit Cases TOP10”and “The Most Dynamic Pharmaceutical VC Institutions in China”. It has also been elected as “Shenzhen TOP10 VC Institutions” for several consecutive years, and once was theme covered by Nature magazine.

Copyright © 2018 2021.All Rights Reserved Rhino Cloud provides enterprise cloud services 犀牛云提供云计算服务